Table 1 Socio-demographic data analysed in (a) all patients and (b) between groups.
From: Comparison of Esmolol and Nicardipine treatment in hypertensive acute ıschemic stroke patients
(a) | Min-max | Mean ± ss | Total (n) | |
|---|---|---|---|---|
Age | 39–93 | 71.5 ± 13.3 | 82 |
n | % | Total (n) | ||
|---|---|---|---|---|
Gender | Male | 41 | 50 | 82 |
Female | 41 | 50 | ||
Thrombolytic | + | 82 | 100 | 82 |
Thrombectomy | + | 82 | 100 | 82 |
(b) | Nicardipine (n = 40) | Esmolol (n = 42) | p | |
|---|---|---|---|---|
Mean ± sd/n (%) | Mean ± sd n (%) | |||
Age | 71.6 ± 11.9 | 71.4 ± 14.7 | 0.928† | |
Gender | Male | 18 (45%) | 23 (54.8%) | 0.507χ2 |
Female | 22 (55%) | 19 (45.2%) | ||
Smoking | + | 8 (20%) | 12 (28.6%) | 0.518 χ2 |
Antiaggregant use | + | 20 (50%) | 13 (31%) | 0.125 x2 |
Antiacoagulant use | + | 2 (5%) | 3 (9.5%) | 0.361χ2 |
Chronic diseases | ||||
AF | + | 16 (40%) | 15 (35.7%) | 0.863χ2 |
Stroke history | + | 11 (27.5%) | 10 (23.8%) | 0.897χ2 |
CAD | + | 13 (32.5%) | 12 (28.6%) | 0.884χ2 |
HT | + | 37 (92.5%) | 30 (71.4%) | 0.013χ2 |
CHF | + | 9 (22.5%) | 9 (21.4%) | 0.907χ2 |
HL | + | 8 (20%) | 6 (14.3%) | 0.347χ2 |
DM | + | 18 (45%) | 10 (23.8%) | 0.073χ2 |
